306 related articles for article (PubMed ID: 21208644)
1. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
2. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
3. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
4. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
6. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
8. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
[TBL] [Abstract][Full Text] [Related]
9. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
12. Association of decreased mitochondrial DNA content with ovarian cancer progression.
Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
[TBL] [Abstract][Full Text] [Related]
13. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
17. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
19. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R
Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
[TBL] [Abstract][Full Text] [Related]
20. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]